Table 2.
Oncological outcome analysis after SBRT.
| Items | Data | % / [min - max] |
|---|---|---|
| MFU (months) | 34 | [12–97] |
| Post-SBRT oncological outcome (# pts) | ||
| Non-progressive disease | 47 | 39.5 |
| Progressive disease | 72 | 60.5 |
| LR alone | 4 | |
| LR + DR | 1 | |
| LR + PR | 1 | |
| DR | 44 | |
| DR + PR | 1 | |
| iBR | 21 | |
| Post-SBRT biochemical response (# pts) | ||
| Response | 77 | 64.7 |
| Stable | 10 | 8.4 |
| Progression | 20 | 16.8 |
| Data missing | 12 | 10.1 |
| Post-SBRT STE (# pts) | ||
| No STE | 62 | 52.1 |
| STE | 57* | 47.9 |
# pts: number of patients; MFU: Median follow-up; SBRT: Stereotactic body radiation therapy; PSA+1: First prostate specific antigen after SBRT; PSASBRT: Prostate specific antigen at the time of SBRT; ADT: first generation androgen deprivation therapy; NHT: novel hormonal therapy; STE: systemic therapy escalation; LR: local relapse in the irradiated field; DR: distant metastatic relapse; PR: prostatic relapse; iBR: isolated Biochemical relapse.
Post-SBRT biochemical response: Response represents PSA+1 < PSASBRT; Stable represents PSA+1 = PSASBRT +/- 0.1 ng/mL; Progression represents PSA+1 > PSASBRT.
*54 patients started ADT and 2 NHT.